Scientific Reports (May 2023)

A novel insight on SARS-CoV-2 S-derived fragments in the control of the host immunity

  • Thais Sibioni Berti Bastos,
  • André Guilherme Portela de Paula,
  • Rebeca Bosso dos Santos Luz,
  • Anali M. B. Garnique,
  • Marco A. A. Belo,
  • Silas Fernandes Eto,
  • Dayanne Carla Fernandes,
  • Fausto Klabund Ferraris,
  • Leticia Gomes de Pontes,
  • Tábata Takahashi França,
  • Leonardo José Gil Barcellos,
  • Flavio P. Veras,
  • Pamela Bermejo,
  • Giovanna Guidelli,
  • Carla Maneira,
  • Fellipe da Silveira Bezerra de Mello,
  • Gleidson Teixeira,
  • Gonçalo Amarante Guimarães Pereira,
  • Bianca H. Ventura Fernandes,
  • Paulo R. S. Sanches,
  • Helyson Lucas Bezerra Braz,
  • Roberta Jeane Bezerra Jorge,
  • Guilherme Malafaia,
  • Eduardo M. Cilli,
  • Danilo da Silva Olivier,
  • Marcos Serrou do Amaral,
  • Renata J. Medeiros,
  • Antonio Condino-Neto,
  • Luciani R. Carvalho,
  • Glaucia M. Machado-Santelli,
  • Ives Charlie-Silva,
  • Jorge Galindo-Villegas,
  • Tárcio Teodoro Braga

DOI
https://doi.org/10.1038/s41598-023-29588-8
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Despite all efforts to combat the pandemic of COVID-19, we are still living with high numbers of infected persons, an overburdened health care system, and the lack of an effective and definitive treatment. Understanding the pathophysiology of the disease is crucial for the development of new technologies and therapies for the best clinical management of patients. Since the manipulation of the whole virus requires a structure with an adequate level of biosafety, the development of alternative technologies, such as the synthesis of peptides from viral proteins, is a possible solution to circumvent this problem. In addition, the use and validation of animal models is of extreme importance to screen new drugs and to compress the organism's response to the disease. Peptides derived from recombinant S protein from SARS-CoV-2 were synthesized and validated by in silico, in vitro and in vivo methodologies. Macrophages and neutrophils were challenged with the peptides and the production of inflammatory mediators and activation profile were evaluated. These peptides were also inoculated into the swim bladder of transgenic zebrafish larvae at 6 days post fertilization (dpf) to mimic the inflammatory process triggered by the virus, which was evaluated by confocal microscopy. In addition, toxicity and oxidative stress assays were also developed. In silico and molecular dynamics assays revealed that the peptides bind to the ACE2 receptor stably and interact with receptors and adhesion molecules, such as MHC and TCR, from humans and zebrafish. Macrophages stimulated with one of the peptides showed increased production of NO, TNF-α and CXCL2. Inoculation of the peptides in zebrafish larvae triggered an inflammatory process marked by macrophage recruitment and increased mortality, as well as histopathological changes, similarly to what is observed in individuals with COVID-19. The use of peptides is a valuable alternative for the study of host immune response in the context of COVID-19. The use of zebrafish as an animal model also proved to be appropriate and effective in evaluating the inflammatory process, comparable to humans.